![](/static/index/imgs/tc2-1.png)
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
BACKGROUND:Vesical Imaging Reporting and Data System (VI-RADS) score is adopted to provide preoperative bladder cancer (BCa) staging. Repeated transurethral resection of bladder tumor (Re-TURBT) is recommended in most of high-risk non-muscle-invasive bladder cancers (HR-NMIBCs) due to possibility of persistent/understaged disease after initial TURBT. No diagnostic tools able to improve patient's stratification for such recommendation exist. OBJECTIVE:To (1) prospectively validate VI-RADS for discriminating between NMIBC and muscle-invasive bladder cancer (MIBC) at TURBT, and (2) evaluate the accuracy of VI-RADS for identifying HR-NMIBC patients who could avoid Re-TURBT and detecting those at higher risk for understaging after TURBT. DESIGN, SETTING, AND PARTICIPANTS:Patients with BCa suspicion were offered multiparametric magnetic resonance imaging (mpMRI) before TURBT. According to VI-RADS, a cutoff of ≥3 to define MIBC was assumed. TURBT reports were compared with preoperative VI-RADS scores to assess accuracy of mpMRI for discriminating between NMIBC and MIBC. HR-NMIBC Re-TURBT reports were compared with preoperatively recorded VI-RADS scores to assess mpMRI accuracy in predicting Re-TURBT outcomes. INTERVENTION:Multiparametric MRI of the bladder before TURBT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values were calculated for mpMRI performance in patients undergoing TURBT and for HR-NMIBC patients candidate for Re-TURBT. Performance of mpMRI was assessed by receiver operating characteristic curve analysis. Ƙ statistics was used to estimate inter- and intrareader variability. RESULTS AND LIMITATIONS:A total of 231 patients were enrolled. Multiparametric MRI showed sensitivity, specificity, PPV, and NPV for discriminating NMIBC from MIBC at initial TURBT of 91.9% (95% confidence interval [CI]: 82.2-97.3), 91.1% (95% CI: 85.8-94.9), 77.5% (95% CI: 65.8-86.7), and 97.1% (95% CI: 93.3-99.1), respectively. The area under the curve (AUC) was 0.94 (95% CI: 0.91-0.97). Among HR-NMIBC patients (n=114), mpMRI before TURBT showed sensitivity, specificity, PPV, and NPV of 85% (95% CI: 62.1-96.8), 93.6% (95% CI: 86.6-97.6), 74.5% (95% CI: 52.4-90.1), and 96.6% (95% CI: 90.5-99.3) respectively, to identify patients with MIBC at Re-TURBT. The AUC was 0.93 (95% CI: 0.87-0.97). CONCLUSIONS:VI-RADS is accurate for discriminating between NMIBC and MIBC. Within HR-NMIBC cases, VI-RADS could, in future, improve the selection of patients who are candidate for Re-TURBT. PATIENT SUMMARY:We investigated the accuracy of Vesical Imaging Reporting and Data System (VI-RADS) score to asses bladder cancer staging before transurethral resection of bladder tumors, and we explored the performance of VI-RADS score as a future preoperative predictive tool for the selection of high-risk non-muscle-invasive bladder cancer patients who are candidate for undergoing early repeated transurethral resection of the primary tumor site.
展开更多
最新影响因子:24.267 | 期刊ISSN:0302-2838 | CiteScore:6.93 |
出版周期:Monthly | 是否OA:YES | 出版年份:1975 |
自引率:6.60% | 研究方向:医学-泌尿学与肾脏学 |
出版地区:NETHERLANDS |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Each issue of ëEuropean Urologyí contains twenty to thirty original articles on a wide range of urological problems. Carefully selected peer-reviewed articles offer useful information on such topics as oncology, impotence, infertility, pediatrics, lithiasis and endourology. Recent advances in techniques, instrumentation, surgery and pediatric urology are supported by topical reviews and papers on applied research to provide readers with a complete guide to international developments in urology. The journalís value as a practical reference for all urologists is further enhanced by clear illustrations and the convenient organization of contributions under separate section headings.
每一期《欧洲泌尿学》都包含20到30篇关于广泛的泌尿学问题的原创文章。精心挑选的同行评审文章提供有关肿瘤学、阳痿、不孕症、儿科、结石和泌尿外科等主题的有用信息。最近在技术、仪器、手术和儿科泌尿外科方面取得的进展得到了专题评论和应用研究论文的支持,为读者提供了泌尿学国际发展的完整指南。通过清晰的插图和在单独的章节标题下方便地组织贡献,进一步增强了期刊对所有泌尿科医生的实用参考价值。通过清晰的插图和在单独的章节标题下方便地组织稿件,杂志作为所有泌尿科医生实用参考的价值进一步增强。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
UROLOGY & NEPHROLOGY (泌尿学与肾脏学) 1区 |
1/76 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
192 | 159 | 33 |
引文计数(2018)
文献(2015-2017)
11512次引用
1662篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Urology
|
#1/97
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
研究方向:CRPC Prostate cancer
接受率: 中等(50%命中)
liting7111
影响因子:13.029
ISSN:1522-8517
研究方向:医学-临床神经学
影响因子:4.506
ISSN:0167-594X
研究方向:医学-临床神经学
影响因子:7.723
ISSN:2162-402X
研究方向:ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
影响因子:4.912
ISSN:1524-9557
研究方向:医学-免疫学
影响因子:12.02
ISSN:2326-6066
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:3.698
ISSN:1750-9378
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:6.63
ISSN:0340-7004
研究方向:医学-免疫学
影响因子:3.077
ISSN:1534-7354
研究方向:医学-全科医学与补充医学
影响因子:0
ISSN:1868-8497
研究方向:ONCOLOGY-ENDOCRINOLOGY & METABOLISM
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
EUROPEAN UROLOGY 投稿经验
(由下方点评分析获得,2人参与,14092人阅读)